Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation
Emily Kozera(Liverpool Hospital), John W. Frew(Rockefeller University), Dillon Mintoff(University of Malta), So Yeon Paek(Baylor Scott & White Health), Martina L. Porter(Beth Israel Deaconess Medical Center), Hans Christian Ring(Bispebjerg Hospital), Nisha Suyien Chandran(National University of Singapore), Hazel H. Oon(National Skin Centre), Erin McMeniman(The University of Queensland), K. Glasenhardt
Cited by 1
Related Papers
Updated<scp>S2</scp>K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (<scp>EADV</scp>)
|Journal of the European Academy of Dermatology and Venereology|2022|247
Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger?
|Dermatology|2018|227
Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument
|British Journal of Dermatology|2009|184
Psoriasis and Microbiota: A Systematic Review
|Diseases|2018|135
The Genomic Architecture of Hidradenitis Suppurativa—A Systematic Review
|Frontiers in Genetics|2022|117